3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
15
Gastrointestinal
6
Other hematologic neoplasm
5
Thoracic
2
Head & Neck
2
Classical hematology
2
Sarcoma
1
Other neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Conditions
Sarcoma
521
Glioblastoma
179
Gliosarcoma
178
Osteosarcoma
155
Dendritic Cell Sarcoma, Interdigitating
114
Brain Neoplasms
113
Gastrointestinal Stromal Tumors
108
Central Nervous System Neoplasms
102
Rhabdomyosarcoma
81
Lymphoma
79
Glioma
79
Burkitt Lymphoma
79
Lymphoma, Non-Hodgkin
78
Recurrence
76
Leiomyosarcoma
75
Precursor Cell Lymphoblastic Leukemia-Lymphoma
73
Lymphoma, Large B-Cell, Diffuse
70
Liposarcoma
69
Astrocytoma
68
Sarcoma, Ewing
67
Lymphoma, Follicular
63
Neuroblastoma
60
Lymphoma, Mantle-Cell
58
Leukemia, Lymphocytic, Chronic, B-Cell
57
Lymphoma, B-Cell, Marginal Zone
56
Lymphoma, Large-Cell, Immunoblastic
54
Hodgkin Disease
54
Leukemia, Myeloid, Acute
53
Neuroectodermal Tumors, Primitive, Peripheral
52
Neoplasm Metastasis
51
Interventions
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
MK 2206
1
Letrozole
1
Lasofoxifene
1
Irinotecan
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled